• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Lorbiecki John Paul

    9/15/22 5:10:15 PM ET
    $ACON
    Medical Specialities
    Health Care
    Get the next $ACON alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Lorbiecki John Paul

    (Last) (First) (Middle)
    8181 ARISTA PLACE
    SUITE 100

    (Street)
    BROOMFIELD CO 80021

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Aclarion, Inc. [ ACON ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    09/15/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Options for Common Stock (right to buy) $1.94 09/15/2022 A 16,455 (1) 09/27/2031 Common Stock 16,455 $0.00 83,389(2) D
    Explanation of Responses:
    1. The shares underlying this option grant will vest in 48 equal monthly installments succeeding the vesting commencement date of October 1, 2021.
    2. In accordance with the reporting person's employment agreement, on September 27, 2021 the reporting person was previously granted 66,934 options with substantially identical terms to the newly granted options reported herein. The options reported herein were granted in order to satisfy the equity grant target set forth in the reporting person's employment agreement.
    /s/ John Paul Lorbiecki 09/15/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ACON alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ACON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Thramann Jeffrey John

    4 - Aclarion, Inc. (0001635077) (Issuer)

    3/28/23 8:30:04 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form 4: Thramann Jeffrey John bought $1,000 worth of Series A Preferred Stock (1 units at $1,000.00)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    2/21/23 4:02:40 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form 4: Ness Brent bought $9,769 worth of shares (18,500 units at $0.53), increasing direct ownership by 1,850% to 19,500 units

    4 - Aclarion, Inc. (0001635077) (Issuer)

    12/29/22 7:57:11 PM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    SEC Filings

    View All

    SEC Form 10-Q filed by Aclarion Inc.

    10-Q - Aclarion, Inc. (0001635077) (Filer)

    8/14/25 1:48:09 PM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Aclarion, Inc. (0001635077) (Filer)

    7/21/25 4:03:28 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form DEFA14A filed by Aclarion Inc.

    DEFA14A - Aclarion, Inc. (0001635077) (Filer)

    7/7/25 4:16:03 PM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Auddia Announces Non-binding Letter of Intent for Business Combination and Restructuring

    Restructuring into a holding company focused on delivering AI and web3 efficiencies to portfolio companies AI efficiencies include discounted AI compute costs, centralized AI model training and engineering, and utilization of AI tools to optimize operations Web3 efficiencies include leveraging treasury strategies and the development of new blockchains and tokens to reinvent market verticals, optimize portfolio company operations, and drive sustainable multiples of NAV   BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Auddia Inc. (NASDAQ:AUUD) (NASDAQ:AUUDW) ("Auddia" or the "Company"), today announced that in follow up to the leadership and strategic changes announce

    8/5/25 6:00:00 AM ET
    $ACON
    $AUUD
    Medical Specialities
    Health Care
    EDP Services
    Technology

    Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts

    Nociscan YOY scan volume increased 132% from Q2 2024 to Q2 2025 fueled by new physician adoption and insurance company coverage in the UK Company has achieved two consecutive quarters of scan volume growth for the first time and expects continued QOQ growth for the remainder of the yearCost-effectiveness analysis demonstrating Nociscan is more effective and less costly than provocative discography published in peer-reviewed journal adding critical evidence in support of payer coverage Pivotal CLARITY trial proceeding on schedule with first patient enrolled to validate Nociscan's ability to improve surgical outcomes for chronic low back pain, with internal interim results expected in Q2 2026R

    8/5/25 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

    Meeting adjourned to Monday, July 21, 2025 at 9:30 a.m. Mountain Time BROOMFIELD, Colo., July 07, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced that its Annual Meeting of Stockholders (the "Annual Meeting") scheduled for July 7, 2025 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statement for the Annual Meeting, filed with the Securities

    7/7/25 4:01:00 PM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    Leadership Updates

    Live Leadership Updates

    View All

    Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

    CLUE is a Multi-center Trial to Identify how Often Nociscan's AI Data Changes the Initial Treatment Plan for Patients With Chronic Low Back Pain Dr. Justin Kubeck Will Initiate CLUE in New Jersey at Ocean Pain and Spine in Toms River BROOMFIELD, CO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the expansion of the multi-center CLUE Trial to New Jersey. Justin Kubeck, MD, orthopedic spine surgeon and founder of Ocean Pain and Spine in Toms

    8/29/24 6:57:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Appoints Nicholas Theodore, MD as Principal Investigator for CLARITY Post-Market Trial Evaluating Nociscan in the Diagnosis and Treatment of Chronic Low Back Pain

    Nicholas Theodore, MD, FACS, FAANS, is Director of Neurosurgical Spine Center, Johns Hopkins, and Professor of Neurosurgery, Orthopaedics and Biomedical Engineering CLARITY is a Post-market, Multi-site Trial That Will Further Evaluate the Role of Nociscan in the Diagnosis and Surgical Ttreatment of Chronic Low Back Pain. CLARITY is Targeted to Begin in the Second Half of 2023. BROOMFIELD, CO, May 02, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pa

    5/2/23 7:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor

    Broomfield, CO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that George Frey MD, Founder of the Colorado Comprehensive Spine Institute, will advise the company as a key opinion leader (KOL). Dr. Frey is a renowned surgeon and inventor with dozens of US and worldwide patents in medical devices, technologies, and methods. Dr. Frey's experiences as a clinician and entrepreneur will provide valuable direction to Aclarion.

    1/17/23 8:29:31 AM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aclarion Inc.

    SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

    11/13/24 3:06:29 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Aclarion Inc.

    SC 13G - Aclarion, Inc. (0001635077) (Subject)

    9/5/24 4:19:39 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Aclarion Inc. (Amendment)

    SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

    3/29/24 5:00:57 PM ET
    $ACON
    Medical Specialities
    Health Care